Phaseline

Companies › Palisade Bio

Palisade Bio: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Immunology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PALI-2108
phosphodiesterase-4 (PDE4) inhibitor
PDE4Phase 2Ulcerative Colitis (UC); Fibrostenotic Crohn's DiseaseOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07428096PALI-2108Phase 1Fibrostenotic Crohn's DiseaseImmunologyJan 2026
NCT07845487PALI-2108Phase 2Ulcerative Colitis (UC)ImmunologyOct 2027

From the company's SEC filings

Cash of $125m on 2026-06-30; operating cash outflow about $23m a year; runway about 64 months at that burn, to Nov 2031; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

PDE4 (1)

Companies with the same targets

Boehringer Ingelheim Chia Tai Tianqing Pharmaceutical Group

Companies built like this

Integrative Skin Science and Research Ganzhou Hemay Pharmaceutical Aclaris Therapeutics Oruka Therapeutics Arcutis Biotherapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.